Quantcast

Latest Senile plaques Stories

2014-03-20 12:33:23

BERLIN and BOSTON, March 20, 2014 /PRNewswire/ -- Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq(TM). This approval comes only four weeks after receiving marketing authorization for Neuraceq(TM) from the European Commission. http://photos.prnewswire.com/prnvar/20140320/NE87281LOGO Neuraceq(TM) is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with...

Unraveling Mysteries Of Amyloid Beta Peptides To Detect And Treat Alzheimer's Disease
2014-02-18 07:41:38

American Institute of Physics Alzheimer's disease has long been marked by progress -- but not the kind of progress the medical community seeks. It is the most common form of dementia among older Americans, and its risk increases with increasing age; for those living with the disease, its ravages get worse over time; and as we move into the 21st century, it will place a greater and greater burden on society. The number of Americans living with Alzheimer's has doubled since 1980 and is...

2013-09-23 23:26:46

Two rare mutations in the human gene that lead to the most common, late-onset variant of Alzheimer's have been identified by Chair Member of the Cure Alzheimer's Disease Research Consortium, Dr. Rudy Tanzi, bringing researchers closer to identifying a cure. Boston, MA (PRWEB) September 23, 2013 In a paper recently published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their...

Alzheimer's Development And Progression Seen Through New Imaging Agents
2013-09-20 04:27:08

redOrbit Staff & Wire Reports - Your Universe Online Researchers have created a new class of imaging agents that could allow them to view the biological processes that occur in the brain during the development and progression of Alzheimer’s disease, according to research appearing in Wednesday’s edition of the journal Neuron. Senior author Dr. Makoto Higuchi of the National Institute of Radiological Sciences in Japan and colleagues have developed a fluorescent compound that...

2013-08-20 17:06:59

In patients with early Alzheimer's disease, disruptions in brain networks emerge about the same time as chemical markers of the disease appear in the spinal fluid, researchers at Washington University School of Medicine in St. Louis have shown. While two chemical markers in the spinal fluid are regarded as reliable indicators of early disease, the new study, published in JAMA Neurology, is among the first to show that scans of brain networks may be an equally effective and less invasive...

2013-06-13 10:06:12

Mount Sinai researchers find reduction in brain plaques in mice after treatment with drugs currently prescribed for other indications Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer's disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One. Led by Giulio Maria Pasinetti, MD, PhD, the Saunders Family Chair and Professor in...

2013-06-12 23:02:20

Mount Sinai researchers find reduction in brain plaques in mice after treatment with drugs currently prescribed for other indications. New York, NY (PRWEB) June 12, 2013 Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer´s disease, according to researchers at The Mount Sinai Medical Center. The findings are published online in the journal PLoS One. Led by Giulio Maria Pasinetti, MD, PhD, the Saunders...

Promising Alzheimer’s Drug Fails In Second Test Round
2013-05-24 12:47:59

Brett Smith for redOrbit.com - Your Universe Online While the recent failure of a potential Alzheimer´s disease treatment is bad news for patients, it serves as an important reminder of the importance of thorough pre-clinical testing of experimental drugs before beginning human trials. According to a group of University of Florida researchers, tests of the anti-cancer drug bexarotene failed to stop the formation of the amyloid brain plaques that are associated with Alzheimer´s...

2013-04-18 12:15:11

Close family members of people with Alzheimer's disease are more than twice as likely as those without a family history to develop silent buildup of brain plaques associated with Alzheimer's disease, according to researchers at Duke Medicine. The study, published online in the journal PLOS ONE on April 17, 2013, confirms earlier findings on a known genetic variation that increases one's risk for Alzheimer's, and raises new questions about other genetic factors involved in the disease that...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related